Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 89 of 121 for:    prostate cancer AND prostate cancer screening | ( Map: United States )

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02443571
Recruitment Status : Completed
First Posted : May 14, 2015
Results First Posted : October 26, 2018
Last Update Posted : December 18, 2018
Sponsor:
Information provided by (Responsible Party):
Blue Earth Diagnostics

Brief Summary:
This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.

Condition or disease Intervention/treatment
Prostatic Neoplasms Radiation: Fluciclovine (18F)

Detailed Description:

This study will collect clinical data from consenting patients (unless a HIPAA waiver or equivalent was granted) who received the PET radiotracer Fluciclovine 18F (FACBC) (a synthetic amino acid analog) for imaging of patients with various cancers at participating sites in the US and Europe.

Data collection will cover baseline medical history and medications in all patients.

The result of PET radiotracer and other imaging findings, and reports of histopathology from biopsied tissue (where available) and in a time window relevant to the use of PET imaging in the diagnosis of primary/recurrent prostate cancer will be recorded.

In all subjects, with regards to safety monitoring, available data for physical examination, vital signs and laboratory test results will be collected from 28 days prior to and out to a 35 day window after Fluciclovine 18F (FACBC) administration.

The major goals of the investigation are to consolidate the safety profile of Fluciclovine 18F (FACBC), to evaluate its use in the detection of local and extraprostatic recurrence of prostate cancer and to evaluate its ability to detect malignancy in patients undergoing screening for primary prostate cancer.


Layout table for study information
Study Type : Observational
Actual Enrollment : 714 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects
Study Start Date : January 2015
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer


Intervention Details:
  • Radiation: Fluciclovine (18F)
    Not applicable. This is an observational study.
    Other Name: FACBC


Primary Outcome Measures :
  1. Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events [ Time Frame: Up to 35 days post Fluciclovine 18F ]
    Treatment-emergent Adverse Events and Treatment-Emergent Serious Adverse Events

  2. Positive Predictive Value of FACBC Compared to Histology to Detect Recurrence in Patients Previously Diagnosed With Prostate Cancer [ Time Frame: Up to 1 year post Fluciclovine 18F ]
    Positive Predictive Value is the percentage of participants with a positive Fluciclovine 18F scan who truly have positive finding in biopsy.

  3. Positive Predictive Value of FACBC to Detect Presence of Malignant Disease in Patients Undergoing Screening for Primary Prostate Cancer [ Time Frame: Up to 1 year post Fluciclovine 18F ]
    Positive Predictive Value is the percentage of participants with a positive Fluciclovine 18F scan who truly have positive finding in biopsy.


Secondary Outcome Measures :
  1. Detection Rate, Sensitivity, Specificity, and Negative Predictive Value in Biochemically Recurrent Prostate Cancer [ Time Frame: Up to 1 year post Fluciclovine 18F ]

    Detection rate is the percentage of participants with positive finding in Fluciclovine 18F scan.

    Sensitivity is the percentage of participants with positive finding in biopsy correctly identified as positive by Fluciclovine 18F scan.

    Specificity is the percentage of participants with negative finding in biopsy correctly identified as negative by Fluciclovine 18F scan.

    Negative Predictive Value is the percentage of participants with a negative Fluciclovine 18F scan who truly don't have positive finding in biopsy.


  2. Detection Rate, Sensitivity, Specificity, and Negative Predictive Value to Detect Presence of Malignant Disease in Patients Undergoing Screening for Primary Prostate Cancer [ Time Frame: Up to 1 year post Fluciclovine 18F ]

    Detection rate is the percentage of participants with positive finding in Fluciclovine 18F scan.

    Sensitivity is the percentage of participants with positive finding in biopsy correctly identified as positive by Fluciclovine 18F scan.

    Specificity is the percentage of participants with negative finding in biopsy correctly identified as negative by Fluciclovine 18F scan.

    Negative Predictive Value is the percentage of participants with a negative Fluciclovine 18F scan who truly don't have positive finding in biopsy.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients (male/female) who underwent PET scanning using fluciclovine (18F) as the radiotracer for the detection of cancer at a clinical site participating in this study.
Criteria

Inclusion Criteria:

  • Patient managed by a site at which ethical committee approval for retrospective data collection under this protocol has been received
  • Patient has received at least one injection of fluciclovine (18F) for the detection of a malignant tumour at any location

Exclusion Criteria:

  • Subjects will be excluded from the analyses if any of the following criteria are met:
  • Patients participating in clinical trials or open access programmes at countries or sites not participating in this study.
  • Patients managed at sites without ethical committee approval for retrospective data collection under this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02443571


Locations
Layout table for location information
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
Italy
University Hospital Sant'Orsola Malpighi
Bologna, Italy, 40138
Norway
Oslo University Hospital
Oslo, Norway, 0424
Aleris Kreftsenter
Oslo, Norway, N-0264
Sponsors and Collaborators
Blue Earth Diagnostics
Investigators
Layout table for investigator information
Study Chair: Penelope Ward, MBBS FFPM Blue Earth Diagnostics

Publications of Results:
Layout table for additonal information
Responsible Party: Blue Earth Diagnostics
ClinicalTrials.gov Identifier: NCT02443571     History of Changes
Other Study ID Numbers: Fluciclovine (18F) - BED - 001
First Posted: May 14, 2015    Key Record Dates
Results First Posted: October 26, 2018
Last Update Posted: December 18, 2018
Last Verified: November 2018
Keywords provided by Blue Earth Diagnostics:
observational study
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases